GFM
GF Fund Management Portfolio holdings
AUM
$4.97B
This Quarter Return
+7.58%
1 Year Return
–
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$4.62B
AUM Growth
–
Cap. Flow
+$4.62B
Cap. Flow
% of AUM
100%
Top 10 Holdings %
Top 10 Hldgs %
48.03%
Holding
637
New
637
Increased
–
Reduced
–
Closed
–
Top Buys
| 1 |
NVIDIA
NVDA
|
$390M |
| 2 |
Apple
AAPL
|
$374M |
| 3 |
Microsoft
MSFT
|
$322M |
| 4 |
Amazon
AMZN
|
$234M |
| 5 |
Meta Platforms (Facebook)
META
|
$194M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Technology | 45.53% |
| 2 | Consumer Discretionary | 17.29% |
| 3 | Communication Services | 14.35% |
| 4 | Healthcare | 6.6% |
| 5 | Consumer Staples | 4.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
476
Grifois
GRFS
$6.89B
| $19.1K | ﹤0.01% |
+2,562
| New | +$19.1K |
|
477
ArriVent BioPharma
AVBP
$819M
| $18.9K | ﹤0.01% |
+708
| New | +$18.9K |
|
478
Adaptive Biotechnologies
ADPT
$1.96B
| $18.6K | ﹤0.01% |
+3,099
| New | +$18.6K |
|
479
Genmab
GMAB
$16.9B
| $18.4K | ﹤0.01% |
+880
| New | +$18.4K |
|
480
Pacira BioSciences
PCRX
$1.19B
| $18.3K | ﹤0.01% |
+970
| New | +$18.3K |
|
|
CSR
481
Centerspace
CSR
$1.01B
| $18.3K | ﹤0.01% |
+276
| New | +$18.3K |
|
482
AbCellera Biologics
ABCL
$1.26B
| $18.2K | ﹤0.01% |
+6,202
| New | +$18.2K |
|
483
Cogent Biosciences
COGT
$1.82B
| $18.1K | ﹤0.01% |
+2,319
| New | +$18.1K |
|
484
uniQure
QURE
$985M
| $18.1K | ﹤0.01% |
+1,023
| New | +$18.1K |
|
485
Kiniksa Pharmaceuticals
KNSA
$2.65B
| $17.3K | ﹤0.01% |
+873
| New | +$17.3K |
|
|
NXRT
486
NexPoint Residential Trust
NXRT
$879M
| $17.2K | ﹤0.01% |
+412
| New | +$17.2K |
|
487
Pliant Therapeutics
PLRX
$114M
| $16.8K | ﹤0.01% |
+1,278
| New | +$16.8K |
|
|
LENZ
488
LENZ Therapeutics
LENZ
$1.2B
| $16.7K | ﹤0.01% |
+577
| New | +$16.7K |
|
489
Vistra
VST
$63.7B
| $16.5K | ﹤0.01% |
+120
| New | +$16.5K |
|
490
Maravai LifeSciences
MRVI
$363M
| $16.2K | ﹤0.01% |
+2,978
| New | +$16.2K |
|
491
CureVac
CVAC
$1.21B
| $16.1K | ﹤0.01% |
+4,710
| New | +$16.1K |
|
492
Castle Biosciences
CSTL
$683M
| $15.7K | ﹤0.01% |
+588
| New | +$15.7K |
|
493
Prothena Corp
PRTA
$460M
| $15.7K | ﹤0.01% |
+1,130
| New | +$15.7K |
|
|
PGRE
494
Paramount Group
PGRE
$1.66B
| $15.5K | ﹤0.01% |
+3,137
| New | +$15.5K |
|
|
SAFE
495
Safehold
SAFE
$1.17B
| $15.5K | ﹤0.01% |
+837
| New | +$15.5K |
|
496
Erasca
ERAS
$457M
| $14.9K | ﹤0.01% |
+5,936
| New | +$14.9K |
|
497
Cullinan Oncology
CGEM
$413M
| $14.9K | ﹤0.01% |
+1,223
| New | +$14.9K |
|
498
Ironwood Pharmaceuticals
IRWD
$188M
| $14.9K | ﹤0.01% |
+3,360
| New | +$14.9K |
|
499
Tyra Biosciences
TYRA
$674M
| $14.8K | ﹤0.01% |
+1,063
| New | +$14.8K |
|
|
AHH
500
Armada Hoffler Properties
AHH
$585M
| $14.7K | ﹤0.01% |
+1,437
| New | +$14.7K |
|